Allosteric networks governing regulation and catalysis of Src-family protein tyrosine kinases: Implications for disease-associated kinases

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 1, 2010, Pages 93-101

  Cheng, Heung Chin ^a   Johnson, Timothy M ^a,b   Mills, Ryan D ^a,b   Chong, Yuh Ping ^b   Chan, Khai Chew ^a   Culvenor, Janetta G ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cancer; Inhibitors; Oncogene; Phosphotransferase; Pp60C Src; Protein tyrosine kinases; Proto oncogene proteins; Src family kinases

Indexed keywords

DASATINIB; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOSTERISM; CARCINOGENESIS; CATALYSIS; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; ENZYME ACTIVATION; ENZYME CONFORMATION; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; HYDROPHOBICITY; MOLECULAR DYNAMICS; STRUCTURE ANALYSIS;

ALLOSTERIC SITE; CATALYSIS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 74049104885     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05237.x     Document Type: Conference Paper

References (47)

1. Martin GS. The hunting of the Src. Nat. Rev. Mol. Cell Biol. 2001 2 : 467 475.
2. Ban K, Gao Y, Amin HM et al. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood 2008 111 : 2904 2908.
3. O'Hare T, Eide CA, Deininger MW. Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia. J. Natl Cancer Inst. 2008 100 : 908 909.
4. Hanna Z, Weng X, Kay DG, Poudrier J, Lowell C, Jolicoeur P. The pathogenicity of human immunodeficiency virus (HIV) type 1 Nef in CD4C/HIV transgenic mice is abolished by mutation of its SH3-binding domain, and disease development is delayed in the absence of Hck. J. Virol. 2001 75 : 9378 9392.
5. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 2008 15 : 1109 1118.
6. Kornev AP, Haste NM, Taylor SS, Eyck LF. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl Acad. Sci. USA 2006 103 : 17783 17788.
7. Shan Y, Seeliger MA, Eastwood MP et al. A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc. Natl Acad. Sci. USA 2009 106 : 139 144.
8. Levinson NM, Seeliger MA, Cole PA, Kuriyan J. Structural basis for the recognition of c-Src by its inactivator Csk. Cell 2008 134 : 124 134.
9. Chong YP, Ia KK, Mulhern TD, Cheng HC. Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases. Biochim. Biophys. Acta 2005 1754 : 210 220.
10. Chong YP, Mulhern TD, Cheng HC. C-Terminal Src kinase (CSK) and CSK-homologous kinase (CHK): Endogenous negative regulators of Src-family protein kinases. Growth Factors 2005 23 : 233 244.
11. Cheng HC, Chong YP, Ia KK, Tan O, Mulhern TD. Csk homologous kinase. UCSD-Nature Molecule Pages (on-line). Epub 9 June 2006 doi :.
12. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997 385 : 602 609.
13. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997 385 : 595 602.
14. Yang S, Banavali NK, Roux B. Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories. Proc. Natl Acad. Sci. USA 2009 106 : 3776 3781.
15. Yang S, Roux B. Src kinase conformational activation. Thermodynamics, pathways, and mechanisms. PLoS Comput. Biol. 2008 4 : E1000047.
16. Adams JA. Kinetic and catalytic mechanisms of protein kinases. Chem. Rev. 2001 101 : 2271 2290.
17. Emrick MA, Lee T, Starkey PJ, Mumby MC, Resing KA, Ahn NG. The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity. Proc. Natl Acad. Sci. USA 2006 103 : 18101 18106.
18. Ten Eyck LF, Taylor SS, Kornev AP. Conserved spatial patterns across the protein kinase family. Biochim. Biophys. Acta 2008 1784 : 238 243.
19. Bukhtiyarova M, Karpusas M, Northrop K, Namboodiri HV, Springman EB. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state. Biochemistry 2007 46 : 5687 5696.
20. Huang K, Wang YH, Brown A, Sun G. Identification of N-terminal lobe motifs that determine the kinase activity of the catalytic domains and regulatory strategies of Src and Csk protein tyrosine kinases. J. Mol. Biol. 2009 386 : 1066 1077.
21. Lerner EC, Smithgall TE. SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo. Nat. Struct. Biol. 2002 9 : 365 369.
22. Lerner EC, Trible RP, Schiavone AP, Hochrein JM, Engen JR, Smithgall TE. Activation of the Src family kinase Hck without SH3-linker release. J. Biol. Chem. 2005 280 : 40832 40837.
23. Cowan-Jacob SW, Fendrich G, Manley PW et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 2005 13 : 861 871.
24. Paster W, Paar C, Eckerstorfer P et al. Genetically encoded Forster resonance energy transfer sensors for the conformation of the Src family kinase Lck. J. Immunol. 2009 182 : 2160 2167.
25. Seeliger MA, Ranjitkar P, Kasap C et al. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 2009 69 : 2384 2392.
26. Dar AC, Lopez MS, Shokat KM. Small molecule recognition of c-Src via the imatinib-binding conformation. Chem. Biol. 2008 15 : 1015 1022.
27. Chong YP, Chan AS, Chan KC et al. C-Terminal Src kinase-homologous kinase (CHK), a unique inhibitor inactivating multiple active conformations of Src family tyrosine kinases. J. Biol. Chem. 2006 281 : 32988 32999.
28. Chong YP, Mulhern TD, Zhu HJ et al. A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity. J. Biol. Chem. 2004 279 : 20752 20766.
29. Sondhi D, Xu W, Songyang Z, Eck MJ, Cole PA. Peptide and protein phosphorylation by protein tyrosine kinase Csk. Insights into specificity and mechanism. Biochemistry 1998 37 : 165 172.
30. Lee S, Lin X, Nam NH, Parang K, Sun G. Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase. Proc. Natl Acad. Sci. USA 2003 100 : 14707 14712.
31. Lee S, Ayrapetov MK, Kemble DJ, Parang K, Sun G. Docking-based substrate recognition by the catalytic domain of a protein tyrosine kinase, C-terminal Src kinase (Csk). J. Biol. Chem. 2006 281 : 8183 8189.
32. Paisan-Ruiz C, Jain S, Evans EW et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004 44 : 595 600.
33. Hernandez DG, Paisan-Ruiz C, McInerney-Leo A et al. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann. Neurol. 2005 57 : 453 456.
34. Belin AC, Westerlund M. Parkinson's disease: A genetic perspective. FEBS J. 2008 275 : 1377 1383.
35. Greggio E, Jain S, Kingsbury A et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006 23 : 329 341.
36. Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 2007 15 : 299 311.
37. Hennequin LF, Ballard P, Boyle FT et al. Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: Synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 2006 16 : 2672 2676.
38. Sim CH, Lio DS, Mok SS et al. C-Terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum. Mol. Genet. 2006 15 : 3251 3262.
39. Jauch R, Jakel S, Netter C et al. Crystal structures of the Mnk2 kinase domain reveal an inhibitory conformation and a zinc binding site. Structure 2005 13 : 1559 1568.
40. 2+-independent neurexin kinase. Cell 2008 133 : 328 339.
41. Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004 47 : 6658 6661.
42. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004 305 : 399 401.
43. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009 9 : 28 39.
44. Rix U, Hantschel O, Durnberger G et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007 110 : 4055 4063.
45. Adrian FJ, Ding Q, Sim T et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2006 2 : 95 102.
46. Nagar B, Hantschel O, Young MA et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003 112 : 859 871.
47. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 1997 18 : 2714 2723.